rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
GeneticVariation
|
BEFREE |
We report on an infant with JMML with somatic KRAS G12A mutation and monosomy 7 who achieved sustained remission following azacitidine monotherapy.
|
31250550 |
2019 |
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
GeneticVariation
|
BEFREE |
In the present study, we report 2 patients with somatic mosaicism for oncogenic NRAS mutations (G12D and G12S) associated with the development of JMML.
|
22753870 |
2012 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The inducible somatic KRAS mutation (G12D) was observed in nine (36%) of CRC patients, and in two (13.3%) of adenoma patients.
|
31692030 |
2020 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer.
|
30876538 |
2019 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The results of the KRAS mutational analysis have shown that the majority of somatic mutations in the KRAS affect only one codon, mainly codon 12(p.G12D) with low frequency in adenomas (13.3%) versus CRCs (36%).
|
30997628 |
2019 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
|
31309326 |
2019 |
rs121913529
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Using the LA2 K-Ras G12D-induced model for lung cancer, we show that Kif2b expression reduces the number of chromosome segregation defects but does not change the incidence of lung tumor lesions.
|
31179849 |
2019 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
rs121913529
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes.
|
30145409 |
2018 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Moreover, comparison of the survival of patients with tumors harboring G12V/A KRAS mutations with those harboring wild-type KRAS gene revealed that G12V/A KRAS mutations are prognostic biomarker for inferior PFS and OS in patients with mCRC treated with bevacizumab in univariate as well as multivariable analyses.
|
26662311 |
2016 |
rs121913529
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Co-administration of BI-2536 and fasudil either in the LSL-KRAS(G12D) mouse model or in a patient tumour explant mouse model of KRAS-mutant lung cancer suppresses tumour growth and significantly prolongs mouse survival, suggesting a strong synergy in vivo and a potential avenue for therapeutic treatment of KRAS-mutant cancers.
|
27193833 |
2016 |
rs121913529
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S).
|
26920031 |
2016 |
rs121913529
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
In this study, we have investigated the delivery and transfection of wild-type (wt-) p53 and microRNA-125b (miR-125b) expressing plasmid DNA, in SK-LU-1 human lung adenocarcinoma cells as well as in Kras(G12D)/p53(fl/fl) (KP) genetically engineered mouse model of lung cancer.
|
26686386 |
2016 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The dominant oncogenic mutations of KRAS are single amino acid substitutions at codon 12, in particular G12D and G12V present in 60% to 70% of pancreatic cancers and 20% to 30% of colorectal cancers.
|
26701267 |
2016 |
rs121913529
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
rs121913529
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
We further observed that oncogenic cooperation between KRAS(G12D) and PIK3CA(H1047R) was accompanied by PI3Kα-mediated regulation of c-MYC, GSK3β, p27(KIP1), survivin, and components of the RB pathway, resulting in accelerated cell division of human or mouse lung cancer-derived cell lines.
|
26567140 |
2015 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The increased cell survival, invasion, intravasation, and specific molecular regulation observed in KRas G12V tumors is consistent with the higher aggressiveness observed in patients with CRC expressing this oncogene.
|
25359494 |
2015 |
rs121913529
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Transgenic expression of activated Kras(G12D) in mouse respiratory epithelium is sufficient to induce lung adenocarcinomas; however, transcriptional mechanisms regulated by K-Ras during the initiation of lung cancer remain poorly understood.
|
24213573 |
2014 |
rs121913529
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
This case suggests possible eradication of the G12D KRAS lung cancer clones by concurrent chemoradiation with panitumumab.
|
23917487 |
2013 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In contrast, in KRAS-mutant CRC cells (DLD-1(G13D) and SW480(G12V)), KRAS knocked-down by KRAS-siRNA led to ERCC1 upregulation and increased oxaliplatin resistance.
|
23209813 |
2012 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
KRAS codon 12 mutations (in particular, c.35G>T), but not codon 13 mutations, are associated with inferior survival in BRAF wild-type colorectal cancer.
|
22753589 |
2012 |
rs121913529
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Using an inducible LSL-KRAS(G12D) model of lung cancer in vivo, we show a transient upregulation of Notch pathway activity in early tumor precursor lesions.
|
21994468 |
2011 |
rs121913529
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
This study demonstrates an association between TRAIL resistance to apoptosis in human pancreatic and lung cancer cell lines and G12D K-ras(12) mutation.
|
20848283 |
2011 |
rs121913529
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
To explore the potential interaction between TSC1 and KRAS activation in lung cancer, mice in which Tsc1 loss and Kras(G12D) expression occur in a small fraction of lung epithelial cells were generated.
|
19966866 |
2010 |